Skip to main content
Pidotimod CAS#: 121808-62-6
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NamePidotimodIUPAC Name(4R)-3--1,3-thiazolidine-4-carboxylic acid  Molecular StructureCAS Registry Number 121808-62-6MDL NumberMFCD00867583SynonymsPidotimod121808-62-6Pidotomod(R)-3-((S)-5-Oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acidPidotimod PGT/1APilimodNSC-759841(R)-3-((S)-5-Oxoprolyl)-4-thiazolidinecarboxylic acidDTXSID0046199Pidotimod (INN)(4R)-3--1,3-thiazolidine-4-carboxylic acid(4R)-3-{carbonyl}-1,3-thiazolidine-4-carboxylic acidNCGC00160516-01Polimod785363R681PidotimodumPigitilPidotimodum 4-Thiazolidinecarboxylic acid, 3-carbonyl]-, (4R)-SMR000466390CCRIS 7271BRN 6636310OnakaThymodolic acidAxilTimodolic acidPilimod (TN)Pidotimod - Bio-XUNII-785363R681PIDOTIMOD PIDOTIMOD (R-(R,S))-3-((5-Oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylic acidPIDOTIMOD (4R)-3-CARBONYL]-4-THIAZOLIDINECARBOXYLIC ACID(R)-3-((S)-(5-Oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure MLS000759528MLS001032108MLS001216453MLS001423953SCHEMBL138407CHEMBL1488165DTXCID8026199Pidotimod, >=98% (HPLC)CHEBI:94618HMS2051C04HMS2231M03HMS3715H06Pharmakon1600-01502322BCP05222HY-B0944Tox21_111865MFCD00867583NSC759841s3106(R)-3-((S)-(5-Oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeureAKOS015896354AC-3493AM90280CCG-100832DB11364KS-5229NC00082NSC 759841(R)-3-carbonyl]-1,3-thiazolidine-4-carboxylic Acid4-Thiazolidinecarboxylic acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (R-(R,S))-NCGC00160516-03BP164260CAS-121808-62-6NS00069185P2147SW197462-2D07261AB00639966-08AB00639966_10AB00639966_11A804790J-502193Q3902720(4R)-3-thiazolidine-4-carboxylic acid;Pidotimod(4R)-3-methyl]-4-thiazolidinecarboxylic acid(4R)-3-{CARBONYL}-1,3-THIAZOLANE-4-CARBOXYLIC ACIDMolecular FormulaC9H12N2O4SMolecular Weight244.27InChIInChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1InChI KeyUUTKICFRNVKFRG-WDSKDSINSA-NCanonical SMILESC1CC(=O)N1C(=O)N2CSC2C(=O)O

Patent InformationPatent IDTitlePublication DateEP276752Derivative of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it1988EP450352Liposome formulations of immunomodulating drugs for the topical and aerosol administrations1991EP572942Oral pharmaceutical compositions for specific colon delivery1993US5369131Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam1994

Physical Data

AppearanceWhite crystalline powder,odorless

Melting Point, °C Solvent (Melting Point) 195 - 197193.99194 - 198195 - 198propan-2-ol, H2O

Density, g·cm-3Measurement Temperature, °C1.50919.84

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Temperature (NMR Spectroscopy), °C Chemical shifts, Spectrum1Hdimethylsulfoxide-d6Chemical shifts, Spectrum13CSpectrum1HChemical shifts, Spectrum1Hdimethylsulfoxide-d6Chemical shifts, Spectrum13Cdimethylsulfoxide-d6Spectrum1Hdimethylsulfoxide-d631.9 - 76.9

Description (IR Spectroscopy)Solvent (IR Spectroscopy)Bandspotassium bromideBands, SpectrumSpectrumKBrBandsKBr

Route of Synthesis (ROS)

Route of Synthesis (ROS) of Pidotimod CAS121808-62-6

ConditionsYieldIn ethanol; water at 5℃; for 5h; Solvent; Temperature; Sonication;Experimental ProcedureTake 0.50g of pidotimod and 40ml of absolute ethanol to form a suspension by sonication. After dissolving the other 0.31g of histidine and 4ml of purified water, slowly add the histidine solution to the aforementioned pidotimod mixture at room temperature. Suspended solution, shake well after adding, cool to 5, continue to stir and crystallize for 5h,Filter to obtain crystalline powder, rinse with absolute ethanol 2 to 3 times,5ml each time, dried under vacuum at 40°C for 10 hours to constant weight to obtain pidotimod histidine salt, crystalline powder, yield 95.2%, purity 99.97% (active ingredient pidotimod detection)95.2%

Safety and Hazards

No data available

Other Data

TransportationUnder room temperature away from lightHS CodeStorageUnder room temperature away from lightShelf Life1 yearMarket Price

DruglikenessLipinski rules componentMolecular Weight244.271logP-1.007HBA6HBD2Matching Lipinski Rules4Veber rules componentPolar Surface Area (PSA)112.01Rotatable Bond (RotB)3Matching Veber Rules2

Quantitative Results1 of 61Comment (Pharmacological Data)Bioactivities presentReferenceDerivative of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it2 of 61Comment (Pharmacological Data)Bioactivities presentReferenceToxicological evaluation of pidotimod 3 of 61Comment (Pharmacological Data)Bioactivities presentReference3-L-(5-thioxo-L-prolyl)thiazolidine-4-carboxylic acid and derivatives therefrom, processes for the preparation thereof and pharmaceutical compositions containing them 4 of 61Comment (Pharmacological Data)Bioactivities presentReferencePidotimod: The state of art5 of 61Comment (Pharmacological Data)Bioactivities presentReferenceEffects of pidotimod soluble powder and immune enhancement of Newcastle disease vaccine in chickens6 of 61Comment (Pharmacological Data)Bioactivities presentReferenceAntimicrobial and immunomodulatory properties and applications of marine-derived proteins and peptides7 of 61Comment (Pharmacological Data)Bioactivities presentReferenceEffects of Pidotimod on recurrent respiratory infections in children with down syndrome: A retrospective Italian study8 of 61Comment (Pharmacological Data)Bioactivities presentReferenceLaser therapy in cutaneous and genital warts: A review article9 of 61Comment (Pharmacological Data)Bioactivities presentReferencePidotimod injection with modified stability, and preparation method thereof10 of 61Comment (Pharmacological Data)Bioactivities presentReferenceAmantadine pidotimod carboxylate and preparation method and application thereof

Use PatternPidotimod CAS#: 121808-62-6 is an immunomodulator suitable for patients with compromised immune function. It can be used for the prevention of acute infections, shorten the duration, and reduce the severity of the disease. It can be used as an adjunctive therapy during the acute infection period.
https://www.chemwhat.com/pidotimod-cas-121808-62-6/

Comments

Post a Comment

Popular posts from this blog

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Benzocyclobutene (BCB) is an organic compound with a rigid molecular structure composed of a conjugated benzene ring and a four-membered ring. Its excellent thermal stability and electrical properties have made it a highly promising candidate for next-generation electronic materials. Historically, its industrial adoption has been constrained by high production costs, complex purification processes, and limited output. However, with growing demand in high-end applications and recent advances in upstream technology, BCB is now poised for industrial-scale deployment. Material Properties and Structural Advantages BCB (C₈H₈) is a non-polar molecule, free of ester, carboxyl, or amide groups, giving it excellent dielectric properties and low moisture absorption. Its dielectric constant (Dk) and dissipation factor (Df) remain stable across wide temperature and frequency ranges—key metrics for ensuring signal integrity in high-frequency, high-speed communication systems. Unlike conventional m...
Post a Comment
Read more

The World's Largest Producer of Squaric Acid Emerges: Watson Leads the Way

In a groundbreaking development for the chemical industry, Watson has officially claimed the title of the world’s largest producer of squaric acid. This achievement marks a significant milestone, positioning the company as a global leader in the production of this highly versatile compound, widely valued in pharmaceuticals, polymer research, and advanced materials. What is Squaric Acid? Squaric acid, also known as quadratic acid, is a four-carbon cyclic diketone with two ketone groups and two hydroxyl groups arranged symmetrically. It is renowned for its stability and strong acidity, making it a unique compound in both organic and inorganic chemistry. Its derivatives find applications in creating advanced coatings, conductive polymers, and as intermediates in drug synthesis. Watson: Redefining Excellence in Squaric Acid Production Watson’s rise to the top of the squaric acid industry is backed by its unmatched production capacity, cutting-edge technology, and unwavering commitment...
Post a Comment
Read more

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Despite BCB’s well-established performance advantages, its commercialization has long been hindered by production cost and scalability challenges. Watson International has made critical breakthroughs in BCB industrialization through integrated innovation in synthesis, purification, and material formulation: Cost Reduction: By optimizing synthetic pathways and improving by-product recovery, Watson has significantly reduced the unit production cost of BCB, enabling cost-effective scaling; High Purity Production: Advanced purification and process control technologies ensure high-purity BCB under mass-production conditions—meeting stringent requirements from high-end electronic manufacturers; Versatile Co-polymerization: Watson’s BCB materials are compatible with other advanced resins such as BMI and PPO, allowing for custom co-polymer design and performance tuning.
Post a Comment
Read more